Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Phase 1

Terminated

Conditions: Neoplasm

Interventions: Drug: preladenant
Biological: pembrolizumab

First Posted Date: 2017-04-04

Last Posted Date: 2019-06-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 10

Registration Number: NCT03099161

Locations: 🇨🇦
Princess Margaret Hospital ( Site 0010), Toronto, Ontario, Canada
🇺🇸
START Midwest ( Site 0001), Grand Rapids, Michigan, United States
🇨🇦
Jewish General Hospital ( Site 0011), Montreal, Quebec, Canada

and more 2 locations

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions: Biological: MK-5160 16 nmol/kg
Biological: Glargine 0.4 U/kg
Biological: MK-5160 32 nmol/kg
Biological: MK-5160 64 nmol/kg
Biological: Placebo to Glargine
Biological: Placebo to MK-5160
Drug: Dextrose
Biological: Glargine 0.6 U/kg

First Posted Date: 2017-03-29

Last Posted Date: 2019-04-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 33

Registration Number: NCT03095651

Locations: 🇺🇸
ProSciento Inc. ( Site 0001), Chula Vista, California, United States

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Phase 3

Completed

Conditions: Small Cell Lung Cancer (SCLC)

Interventions: Biological: Pembrolizumab
Drug: Normal saline solution
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2017-02-28

Last Posted Date: 2022-10-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 453

Registration Number: NCT03066778

Locations: 🇨🇦
William Osler Health System (Brampton Civic Hospital) ( Site 0161), Brampton, Ontario, Canada
🇺🇸
Weinberg Cancer Institute at Franklin Square ( Site 1210), Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital ( Site 1203), Boston, Massachusetts, United States

and more 145 locations

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: MK-4621

First Posted Date: 2017-02-27

Last Posted Date: 2019-07-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 15

Registration Number: NCT03065023

Locations: 🇩🇪
Universitätsklinikum Carl Gustav Carus - Phase I Unit, Dresden, Germany
🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇪🇸
START - Hospital Universitario HM Sanchinarro - Phase I Unit, Madrid, Spain

and more 3 locations

Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: placebo
Biological: pembrolizumab
Other: best supportive care (BSC)

First Posted Date: 2017-02-23

Last Posted Date: 2024-11-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 453

Registration Number: NCT03062358

Locations: 🇨🇳
Beijing Cancer Hospital ( Site 0010), Beijing, China
🇨🇳
Zhongshan Hospital Fudan University ( Site 0012), Shanghai, China
🇨🇳
Renji Hosp,Shanghai Jiao Tong University School of Medicine ( Site 0017), Shanghai, China

and more 38 locations

An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)

Phase 2

Completed

Conditions: Schizophrenia, Acute Episode

Interventions: Drug: MK-8189
Drug: Risperidone
Drug: Placebo matching MK-8189
Drug: Placebo matching risperidone

First Posted Date: 2017-02-16

Last Posted Date: 2024-08-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 224

Registration Number: NCT03055338

Locations: 🇺🇸
CNRI - Los Angeles, LLC ( Site 0026), Pico Rivera, California, United States
🇺🇸
Artemis Institute for Clinical Research ( Site 0027), San Diego, California, United States
🇺🇸
Radiant Research - Atlanta ( Site 0008), Atlanta, Georgia, United States

and more 25 locations

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Phase 3

Active, not recruiting

Conditions: Head and Neck Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Placebo
Drug: Cisplatin
Radiation: Accelerated Fractionation (AFX) Radiotherapy
Radiation: Standard Fractionation (SFX) Radiotherapy

First Posted Date: 2017-02-02

Last Posted Date: 2024-02-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 804

Registration Number: NCT03040999

Locations: 🇺🇸
UCLA Medical Center ( Site 0273), Los Angeles, California, United States
🇵🇱
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1007), Gdynia, Poland
🇵🇱
Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie ( Site 1000), Warszawa, Poland

and more 148 locations

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Epirubicin
Drug: Placebo
Drug: Cyclophosphamide

First Posted Date: 2017-01-30

Last Posted Date: 2025-01-09

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1174

Registration Number: NCT03036488

Locations: 🇦🇺
Royal Adelaide Hospital ( Site 2008), Adelaide, South Australia, Australia
🇺🇸
Cedars Sinai Medical Center ( Site 0091), Los Angeles, California, United States
🇺🇸
The University of Chicago Medical Center ( Site 0047), Chicago, Illinois, United States

and more 190 locations

Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

Phase 3

Terminated

Conditions: Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: Pembrolizumab
Drug: Paclitaxel

First Posted Date: 2017-01-12

Last Posted Date: 2023-03-30

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 94

Registration Number: NCT03019588

Locations: 🇨🇳
China Medical University Hospital. ( Site 0226), Taichung, Taiwan
🇨🇳
Sir Sun Sun Shaw Hosp, Zhejiang Univ,Oncology dept. ( Site 0016), Hangzhou, China
🇨🇳
The First Affiliated Hospital of Zhejiang University ( Site 0004), Hangzhou, China

and more 33 locations

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Phase 1

Completed

Conditions: Solid Tumors
Lymphoma

Interventions: Drug: Ulevostinag
Biological: Pembrolizumab

First Posted Date: 2017-01-04

Last Posted Date: 2024-02-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 156

Registration Number: NCT03010176

Locations: 🇺🇸
Huntsman Cancer Institute ( Site 0004), Salt Lake City, Utah, United States
🇺🇸
Mount Sinai Hospital ( Site 0002), New York, New York, United States
🇺🇸
UCSF ( Site 0015), San Francisco, California, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy